303 related articles for article (PubMed ID: 23106273)
1. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.
Wolff KA; Nguyen L
Expert Rev Anti Infect Ther; 2012 Sep; 10(9):971-81. PubMed ID: 23106273
[TBL] [Abstract][Full Text] [Related]
2. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
[TBL] [Abstract][Full Text] [Related]
3. Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of
de Welzen L; Eldholm V; Maharaj K; Manson AL; Earl AM; Pym AS
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993337
[TBL] [Abstract][Full Text] [Related]
4. Preparation and biological evaluation of ethionamide-mesoporous silicon nanoparticles against Mycobacterium tuberculosis.
Vale N; Correia A; Silva S; Figueiredo P; Mäkilä E; Salonen J; Hirvonen J; Pedrosa J; Santos HA; Fraga A
Bioorg Med Chem Lett; 2017 Feb; 27(3):403-405. PubMed ID: 28057421
[TBL] [Abstract][Full Text] [Related]
5. Targeting intracellular p-aminobenzoic acid production potentiates the anti-tubercular action of antifolates.
Thiede JM; Kordus SL; Turman BJ; Buonomo JA; Aldrich CC; Minato Y; Baughn AD
Sci Rep; 2016 Dec; 6():38083. PubMed ID: 27905500
[TBL] [Abstract][Full Text] [Related]
6. Targeting antibiotic resistance mechanisms in Mycobacterium tuberculosis: recharging the old magic bullets.
Nguyen L
Expert Rev Anti Infect Ther; 2012 Sep; 10(9):963-5. PubMed ID: 23106271
[No Abstract] [Full Text] [Related]
7. Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
Costa-Gouveia J; Pancani E; Jouny S; Machelart A; Delorme V; Salzano G; Iantomasi R; Piveteau C; Queval CJ; Song OR; Flipo M; Deprez B; Saint-André JP; Hureaux J; Majlessi L; Willand N; Baulard A; Brodin P; Gref R
Sci Rep; 2017 Jul; 7(1):5390. PubMed ID: 28710351
[TBL] [Abstract][Full Text] [Related]
8. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis.
Vilchèze C; Av-Gay Y; Attarian R; Liu Z; Hazbón MH; Colangeli R; Chen B; Liu W; Alland D; Sacchettini JC; Jacobs WR
Mol Microbiol; 2008 Sep; 69(5):1316-29. PubMed ID: 18651841
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of thioamide drug action against tuberculosis and leprosy.
Wang F; Langley R; Gulten G; Dover LG; Besra GS; Jacobs WR; Sacchettini JC
J Exp Med; 2007 Jan; 204(1):73-8. PubMed ID: 17227913
[TBL] [Abstract][Full Text] [Related]
10. Consistency of standard laboratory strain Mycobacterium tuberculosis H 37 Rv with ethionamide susceptibility testing.
Lakshmi R; Kumar V; Rahman F; Ramachandran R
Indian J Med Res; 2012 May; 135(5):672-4. PubMed ID: 22771598
[TBL] [Abstract][Full Text] [Related]
11. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.
Brossier F; Veziris N; Truffot-Pernot C; Jarlier V; Sougakoff W
Antimicrob Agents Chemother; 2011 Jan; 55(1):355-60. PubMed ID: 20974869
[TBL] [Abstract][Full Text] [Related]
12. [GenoType MTBDR plus 1.0® for the detection of cross-resistance between isoniazide and ethionamide in isolates of multidrug-resistant Mycobacterium tuberculosis].
Rueda J; Realpe T; Mejía G; Zapata E; Robledo J
Biomedica; 2015; 35(4):541-8. PubMed ID: 26844443
[TBL] [Abstract][Full Text] [Related]
13. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.
Niehaus AJ; Mlisana K; Gandhi NR; Mathema B; Brust JC
PLoS One; 2015; 10(9):e0135003. PubMed ID: 26332235
[TBL] [Abstract][Full Text] [Related]
14. A katG S315T or an ahpC promoter mutation mediate Mycobacterium tuberculosis resistance to 2-thiophen carboxylic acid hydrazide, an inhibitor resembling the anti-tubercular drugs Isoniazid and Ethionamide.
Franceschelli JJ; Belardinelli JM; Tong P; Loftus B; Recio-Balsells A; Labadié GR; Gordon SV; Morbidoni HR
Tuberculosis (Edinb); 2018 Sep; 112():69-78. PubMed ID: 30205971
[TBL] [Abstract][Full Text] [Related]
15. [Cross-resistance between isoniazid and ethionamide and its strong association with mutation C-15T in Mycobacterium tuberculosis isolates from Peru].
Sandoval R; Monteghirfo M; Salazar O; Galarza M
Rev Argent Microbiol; 2020; 52(1):36-42. PubMed ID: 31255368
[TBL] [Abstract][Full Text] [Related]
16. Bacterial Genome-Wide Association Identifies Novel Factors That Contribute to Ethionamide and Prothionamide Susceptibility in Mycobacterium tuberculosis.
Hicks ND; Carey AF; Yang J; Zhao Y; Fortune SM
mBio; 2019 Apr; 10(2):. PubMed ID: 31015328
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of the antituberculosis drug ethionamide.
Vale N; Gomes P; Santos HA
Curr Drug Metab; 2013 Jan; 14(1):151-8. PubMed ID: 23215813
[TBL] [Abstract][Full Text] [Related]
18. Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.
Rueda J; Realpe T; Mejia GI; Zapata E; Rozo JC; Ferro BE; Robledo J
Antimicrob Agents Chemother; 2015 Dec; 59(12):7805-10. PubMed ID: 26369965
[TBL] [Abstract][Full Text] [Related]
19. Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB.
Nonghanphithak D; Kaewprasert O; Chaiyachat P; Reechaipichitkul W; Chaiprasert A; Faksri K
PLoS One; 2020; 15(12):e0244829. PubMed ID: 33382836
[TBL] [Abstract][Full Text] [Related]
20. Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
Choi J; Park SJ; Jee JG
Eur J Med Chem; 2015 Dec; 106():157-66. PubMed ID: 26544630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
